Leveraging therapeutic potential of multi-targeted siRNA inhibitors

Future Medicinal Chemistry

Volumn 1, Issue 9, 2009, Pages 1671-1681

  Ge, Qing ^a   Xu, John J ^a   Evans, David M ^a   Mixson, A James ^b   Yang, Harry Y ^a   Lu, Patrick Y ^a  

^a Sirnaomics Inc   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; DOUBLE STRANDED RNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOSOME; MATRIX METALLOPROTEINASE; PROTAMINE; RIBONUCLEASE; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; VASCULOTROPIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CLINICAL TRIAL; DRUG DESIGN; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INNATE IMMUNITY; LIVER CELL CARCINOMA; NEOPLASM; NONHUMAN; PLASMID; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; RNA VIRUS; VIRUS INFECTION; VIRUS REPLICATION; VIRUS RESISTANCE;

HUMANS; NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING; VIRUS DISEASES;

EID: 77953445954     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.09.131     Document Type: Review

References (92)

1. Tabarsi P, Saber-Tehrani AS, Baghaei P et al. Early initiation of antiretroviral therapy results in decreased morbidity and mortality among patients with TB and HIV. J. Int. AIDS Soc. 12(1), 14 (2009).
2. Dickinson L, Khoo S, Back D. Pharmacokinetics and drug-drug interactions of antiretrovirals: an update. Antiviral Res. DOI:10.1016/j.antiviral.2009.07. 017 (2009) (Epub ahead of print).
3. Novina CD, Sharp PA. The RNAi revolution. Nature 430(6996), 161-164 (2004).
4. Birmingham A, Anderson E, Sullivan K et al. A protocol for designing siRNAs with high functionality and specificity. Nat. Protoc. 2(9), 2068-2078 (2007).
5. von Eije KJ, Ter Brake O, Berkhout B. Stringent testing identifies highly potent and escape-proof anti-HIV short hairpin RNAs. J. Gene Med. 11(6), 459-467 (2009).
6. Gitlin L, Stone JK, Andino R. Poliovirus escape from RNA interference: short interfering RNA-target recognition and implications for therapeutic approaches. J. Virol. 79(2), 1027-1035 (2005).
7. Kim BQ, Tang QQ, Rouse BT. Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor-pathway genes; therapeutic strategy for herpetic stromal keratitis. Am. J. Pathol. 165(6), 2177-2184 (2004).
8. Song EW, Zhu P, Lee SK et al. Antibody mediated in vivo delivery of small interfering RNA via cell surface receptors. Nature Biotechnol. 23(6), 709-717 (2005).
9. Tummalapalli P, Gondi CS, Dinh DH, Gujrati M, Rao JS. RNA interferencemediated targeting of urokinase plasminogen activator receptor and matrix metalloproteinase-9 gene expression in the IOMM-Lee malignant meningioma cellline inhibits tumor growth, tumor cell invasion and angiogenesis. Int. J. Oncol. 31, 5-17 (2007).
10. Shahzad MM, Lu C, Lee JW et al. Daul targeting of EphA2 and FAK in overian carcinoma. Cancer Biol. Ther. 8(11), 1027-1034 (2009).
11. Filipowicz W. RNAi: the nuts and bolts of the RISC machine. Cell 122(1), 17-20 (2005).
12. Jinek M, Doudna JA. A three-dimensional view of the molecular machinery of RNA interference. Nature 457(7228), 405-412 (2009).
13. Hammond SM, Bernstein E, Beach D, Hannon GJ. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 404(6775), 293-296 (2000).
14. Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101(1), 25-33 (2000).
15. Kok KH, Ng MH, Ching YP, Jin DY. Human TRBP and PACT directly interact with each other and associate with dicer to facilitate the production of small interfering RNA. J. Biol. Chem. 282(24), 17649-17657 (2007).
16. Chendrimada TP, Gregory RI, Kumaraswamy E et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 436(7051), 740-744 (2005).
17. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 15(2), 188-200 (2001).
18. Lee YS, Nakahara K, Pham JW et al. Distinct roles for Drosophila dicer-1 and dicer-2 in the siRNA/miRNA silencing pathways. Cell 117(1), 69-81 (2004).
19. Schwarz DS, Tomari Y, Zamore PD. The RNA-induced silencing complex is a Mg2+-dependent endonuclease. Curr. Biol. 14(9), 787-791 (2004).
20. Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. Cell 115(2), 209-216 (2003).
21. Siomi H, Siomi MC. On the road to reading the RNA-interference code. Nature 457, 396-404 (2009)
22. Nykanen A, Haley B, Zamore PD. ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell 107(3), 309-321 (2001).
23. Martinez J, Patkaniowska A, Urlaub H, Luhrmann R, Tuschl T. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 110(5), 563-574 (2002).
24. Hammond SM, Boettcher S, Caudy AA, Kobayashi R, Hannon GJ. Argonaute2, a link between genetic and biochemical analyses of RNAi. Science 293(5532), 1146-1150 (2001).
25. Okamura K, Ishizuka A, Siomi H, Siomi MC. Distinct roles for Argonaute proteins in small RNA-directed RNA cleavage pathways. Genes Dev. 18(14), 1655-1666 (2004).
26. Ma JB, Yuan YR, Meister G, Pei Y, Tuschl T, Patel DJ. Structural basis for 5′-end-specific recognition of guide RNA by the A. fulgidus Piwi protein. Nature 434(7033), 666-670 (2005).
27. Nowotny M, Gaidamakov SA, Crouch RJ, Yang W. Crystal structures of RNase H bound to an RNA/DNA hybrid: substrate specificity and metal-dependent catalysis. Cell 121(7), 1005-1016 (2005).
28. Natt F. siRNAs in drug discovery: target validation and beyond. Curr. Opin. Mol. Ther. 9(3), 242-247 (2007).
29. Iorns E, Lord CJ, Turner N, Ashworth A. Utilizing RNA interference to enhance cancer drug discovery. Nat. Rev. Drug Discov. 6(7), 556-568 (2007).
30. Holen T, Amarzguioui M, Wiiger MT, Babaie E, Prydz H. Positional effects of short interfering RNAs targeting the human coagulation trigger tissue factor. Nucleic Acids Res. 30(8), 1757-1766 (2002).
31. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A. Rational siRNA design for RNA interference. Nat. Biotechnol. 22(3), 326-330 (2004).
32. Zheng BJ. Prophylactic and therapeutic effects of small interfering RNA targeting SARS-coronavirus. Antiviral Therapy 9, 365-374 (2004).
33. Li BJ. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat. Med. 11(9), 944-951 (2005).
34. Castanotto D, Sakurai K, Lingeman R et al. Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Res. 35(15), 5154-5164 (2007).
35. Grimm D, Streetz KL, Jopling CL et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441(7092), 537-541 (2006).
36. Jackson AL, Bartz SR, Schelter J et al. Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 21(6), 635-637 (2003).
37. Birmingham A, Anderson EM, Reynolds A et al. 3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat. Methods. 3(3), 199-204 (2006).
38. Lin X, Ruan X, Anderson MG et al. siRNA-mediated off-target gene silencing triggered by a 7 nt complementation. Nucleic Acids Res. 33(14), 4527-4535 (2005).
39. Judge A, MacLachlan I. Overcoming the innate immune response to small interfering RNA. Hum. Gene Ther. 19(2), 111-124 (2008).
40. Scacheri PC, Rozenblatt-Rosen O, Caplen NJ et al. Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc. Natl Acad. Sci. USA 101(7), 1892-1897 (2004).
41. Khan AA, Betel D, Miller ML, Sander C, Leslie CS, Marks DS. Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nat. Biotechnol. 27(6), 549-555 (2009)
42. Rao DD, Senzer N, Cleary MA, Nemunaitis J. Comparative assessment of siRNA and shRNA off target effects: what is slowing clinical development. Cancer Gene Ther. 16(11), 807-809. (2009).
43. Kittler R, Surendranath V, Heninger AK et al. Genome-wide resources of endoribonuclease-prepared short interfering RNAs for specific loss-of-function studies. Nat. Methods 4(4), 337-344 (2007).
44. Robbins M, Judge A, Ambegia E et al. Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum. Gene Ther. 19(10), 991-999 (2008).
45. Jackson AL, Burchard J, Leake D et al. Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 12(7), 1197-1205 (2006).
46. Ui-Tei K, Naito Y, Zenno S et al. Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect. Nucleic Acids Res. 36(7), 2136-2151 (2008).
47. Chiu YL, Rana TM. RNAi in human cells: basic structural and functional features of small interfering RNA. Mol. Cell 10(3), 549-561 (2002).
48. Rossi JJ, June CH, Kohn DB. Genetic therapies against HIV. Nat. Biotechnol. 25(12), 1444-1454 (2007).
49. Chen Y, Cheng G, Mahato RI. RNAi for treating hepatitis B viral infection. Pharm. Res. 25(1), 72-86 (2008).
50. Ogata N, Alter HJ, Miller RH, Purcell RH. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc. Natl Acad. Sci. USA 88(8), 3392-3396 (1991).
51. Okamoto H, Kojima M, Okada S et al. Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability. Virology 190(2), 894-899 (1992).
52. Drake JW, Holland JJ. Mutation rates among RNA viruses. Proc. Natl Acad. Sci. USA 96(24), 13910-13913 (1999).
53. Parvin JD, Moscona A, Pan WT, Leider JM, Palese P. Measurement of the mutation rates of animal viruses: influenza A virus and poliovirus type 1. J. Virol. 59(2), 377-383 (1986).
54. Enomoto N, Kurosaki M, Tanaka Y, Marumo F, Sato C. Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by single-strand conformation polymorphism analysis. J. Gen. Virol. 75, 1361-1369 (1994).
55. Guillou-Guillemette HL, Vallet S, Gaudy-Graffin C et al. Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy. World J. Gastroenterol. 13(17), 2416-2426 (2007).
56. Gitlin L, Karelsky S, Andino R. Short interfering RNA confers intracellular antiviral immunity in human cells. Nature 418(6896), 430-434 (2002).
57. Wilson JA, Richardson CD. Hepatitis C virus replicons escape RNA interference induced by a short interfering RNA directed against the NS5b coding region. J. Virol. 79(11), 7050-7058 (2005).
58. Konishi M, Wu CH, Kaito M et al. siRNA-resistance in treated HCV replicon cells is correlated with the development of specific HCV mutations. J. Viral Hepat. 13(11), 756-761 (2006).
59. Nishitsuji H, Kohara M, Kannagi M, Masuda T. Effective suppression of human immunodeficiency virus type 1 through a combination of short- or long-hairpin RNAs targeting essential sequences for retroviral integration. J. Virol. 80(15), 7658-7666 (2006).
60. Boden D, Pusch O, Lee F, Tucker L, Ramratnam B. Human immunodeficiency virus type 1 escape from RNA interference. J. Virol. 77(21), 11531-11535 (2003).
61. Das AT, Brummelkamp TR, Westerhout EM et al. Human immunodeficiency virus type 1 escapes from RNA interferencemediated inhibition. J. Virol. 78(5), 2601-2605 (2004).
62. ter Brake O, Konstantinova P, Ceylan M, Berkhout B. Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol. Ther. 14(6), 883-892 (2006).
63. Sabariegos R, Gimenez-Barcons M, Tapia N, Clotet B, Martinez MA. Sequence homology required by human immunodeficiency virus type 1 to escape from short interfering RNAs. J. Virol. 80(2), 571-577 (2006).
64. Unwalla HJ, Li HT, Bahner I, Li MJ, Kohn D, Rossi JJ. Novel Pol II fusion promoter directs human immunodeficiency virus type 1-inducible coexpression of a short hairpin RNA and protein. J. Virol. 80(4), 1863-1873 (2006).
65. Westerhout EM, Ooms M, Vink M, Das AT, Berkhout B. HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res. 33(2), 796-804 (2005).
66. Leonard JN, Shah PS, Burnett JC, Schaffer DV. HIV evades RNA interference directed at TAR by an indirect compensatory mechanism. Cell Host Microbe 4(5), 484-494 (2008).
67. von Eije KJ, ter Brake O, Berkhout B. Human immunodeficiency virus type 1 escape is restricted when conserved genome sequences are targeted by RNA interference. J. Virol. 82(6), 2895-2903 (2008).
68. Novina CD, Murray MF, Dykxhoorn DM et al. siRNA-directed inhibition of HIV-1 infection. Nat. Med. 8(7), 681-686 (2002).
69. Martinez MA, Clotet B, Este JA. RNA interference of HIV replication. Trends Immunol. 23(12), 559-561 (2002).
70. Chang H. RNAi-mediated knockdown of target genes: a promising strategy for pancreatic cancer research. Cancer Gene Ther. 14(8), 677-685 (2007)
71. Dykxhoorn DM, Chowdhury D, Lieberman J. RNA interference and cancer: endogenous pathways and therapeutic approaches. Adv. Exp. Med. Biol. 615, 299-329 (2008).
72. Arbuthnot P, Thompson LJ. Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma. World J. Gastroenterol. 14(11), 1670-1681 (2008).
73. Lu PY, Xie FY, Woodle M. Modulation of angiogenesis pathway using siRNA for gene function validation and novel therapeutics. Trends Mol. Med. 11(3), 104-113 (2005).
74. Pourgholami MH, Morris DL. Inhibitors of vascular endothelial growth factor in cancer. Cardiovasc. Hematol. Agents Med. Chem. 6(4), 343-347 (2008).
75. Roy R, Yang J, Moses MA. Matrix Metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J. Clin. Oncol. 27(31), 5287-5297 (2009).
76. Lakka SS, Rao JS. Antiangiogenic therapy in brain tumors. Expert Rev. Neurother. 8(1), 1457-1473 (2008).
77. McCarty JH. Integrin-mediated regulation of neurovascular development, physiology and disease. Cell Adh. Migr. 3(2), 211-215 (2009).
78. Wirapati P, Sotiriou C, Kunkel S et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 10(4), R65 (2008).
79. Rao DD, Vorhies JS, Senzer N, Nemunaitis J. siRNA vs. shRNA: similarities and differences. Adv. Drug Deliv. Rev. 61(9), 746-759 (2009).
80. Kunigal S, Lakka SS, Gondi CS, Estes N, Rao JS. RNAi-mediatged downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth. Int. J. Cancer 121, 2307-2316 (2007)
81. Lakka SS, Gondi CS, Dinh DH et al. Specific interference of uPAR and MMP-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth and angiogenesis in gliomas. J. Biol. Chem. 280, 21882-21892 (2005)
82. Gondi CS, Lakka SS, Dinh DH, Olivero WC, Gujrati M, Rao JS. Intraperitoneal injection of an hpRNA-expressing plasmid targeting uPAR and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice. Clin. Cancer Res. 13, 4051-4060 (2007).
83. Kargiotis O, Chetty C, Gogineni V et al. uPA/ uPAR downregulation inhibits radiationinduced migration, invasion and angiogenesis in IOMM-Lee meningioma cells and decreases tumor growth in vivo. Int. J. Oncol. 33(5), 937-947 (2008).
84. Lakka SS, Gondi CS, Yanamandra N et al. Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene 23, 4681-4689 (2004).
85. Gondi CS, Lakka SS, Dinh DH, Olivero WC, Gujrati M, Rao JS. RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Oncogene 23, 8486-8496 (2004).
86. Takeshita F, Minakuchi Y, Nagahara S et al. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc. Natl Acad. Sci. USA 102, 12177-12182 (2005).
87. News Release. Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY), April 3, 2009.
88. Kunze D, Wuttig D, Fuessel S et al. Multitarget siRNA inhibition of antiapoptotic genes (XIAP, BCL2, BCL-X(L)) in bladder cancer cells. Anticancer Res. 28(4B), 2259-2263 (2008).
89. Zhao M, He HW, Sun HX et al. Dual knockdown of N-ras and epiregulin synergistically suppressed the growth of human hepatoma cells. Biochem. Biophys. Res. Commun. 387(2), 239-244 (2009).
90. RNAi & Antisense Therapeutics Technology & Business Review. Technology Catalysts International Corporation (2008).
91. Poeck H. 5′-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat. Med. 14(11), 1256-1263 (2008).
92. MacDiarmid JA. Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat. Biotechnol. 27(7), 643-654 (2009).